TBCRCTranslational Breast Cancer Research Consortium
TBCRCTampa Bay Community Reinvestment Corporation (Florida)
References in periodicals archive ?
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
The study evaluated the association between the Recurrence Score and time to progression and overall survival in patients with advanced breast cancer enrolled in TBCRC 013, a registry evaluating the primary tumor in patients presenting with stage IV disease.
TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer.